HemaChrom, a digital startup company measuring blood hemoglobin levels with smartphone technology, has won phase 1 of the National Institutes of Health’s RADx Tech for Maternal Health Challenge.
A digital health startup company known as HemaChrome recently won phase 1 of the National Institutes of Health’s (NIH) RADx Tech for Maternal Health Challenge.
Their winning smartphone technology is capable of measuring blood hemoglobin levels instantly and noninvasively. Young Kim, MD, founder and chief science officer of HemaChrome, developed the technology.
“Blood hemoglobin tests are among the most common laboratory tests because they are an indicator of a variety of diseases and disorders,” Kim said. “In fact, they are the most common laboratory tests conducted among obstetric patients. However, more than 2.2 million childbearing women in the U.S. have limited access to such testing.
According to Kim, invasive and expensive venous blood draws are often used to perform blood hemoglobin tests, needing high end equipment and trained professionals to complete the tests on-site. Using the app, blood hemoglobin tests will be available to everyone and easily accessible, with less barriers and a reduced cost.
A cash prize was rewarded to HemaChrome for winning phase 1 of the challenge. The technical and commercial viability of their product was tested by a panel of medical, scientific, and business experts. Now, they will receive in-house and in-kind support from the NIH which will speed the development, validation, and commercialization of the technology.
In the time leading to phase 2 of the challenge, biweekly meetings will occur between HemaChrome and NIH RADx experts.
“We are working with the NIH RADx team to identify and mitigate key risk factors for the accelerated development and implementation of our technology,” Kim said. “If we progress to the next phase, we will work with them to independently test and verify our technology’s performance and usability.
Kim’s research has been published in journals such as the November 2022 issue of Blood and the June 2020 issue of Optica, and he plans to write further papers and conduct future clinical studies.
Reference
Purdue-connected digital health startup wins phase 1 of NIH competition for maternal health. Purdue University. February 15, 2023. Accessed March 8, 2023. https://www.purdue.edu/newsroom/releases/2023/Q1/purdue-connected-digital-health-startup-wins-phase-1-of-nih-competition-for-maternal-health.html
Rising endometriosis rates linked to increased pregnancy complications
May 19th 2024A new study presented at the 2024 ACOG meeting reveals a significant rise in endometriosis among pregnant women over the past 20 years, linking the condition to increased obstetric and neonatal complications.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Impact of antiepileptic medications and sex hormones on maternal and child outcomes in epilepsy
May 16th 2024Paula Emanuela Voinescu, MD, PhD, director of the Women's Epilepsy Program at Brigham and Women's Hospital, talked about the influence of sex hormones on maternal outcomes in pregnant women with epilepsy treated with antiseizure medication.
Read More
Echogenic Mass identified as key predictor for retained products of conception
May 13th 2024Discover how recent findings highlight the significance of echogenic masses in accurately diagnosing post-pregnancy complications, shedding light on effective management strategies and reducing the need for invasive interventions.
Read More